The GPR75 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population designed to disrupt GPR75 gene expression in the HeLa background. This product provides a heterogeneous pool of edited cells, offering a robust loss-of-function model for studying the orphan G protein-coupled receptor GPR75. The polyclonal format ensures genetic diversity within the knockout population, enabling the interrogation of GPR75 function without clonal selection bias.
HeLa cells, derived from a cervical adenocarcinoma of Henrietta Lacks, are an extensively characterized immortalized cell line widely utilized in cancer biology and signal transduction research. These cells harbor HPV18 integration and display robust growth and transfection efficiency, making them a versatile host for CRISPR-based gene disruption. The HeLa background provides a well-defined platform for investigating GPCR-mediated signaling in a human cancer context.
GPR75 is an orphan receptor implicated in metabolic regulation and energy homeostasis. Mechanistically, it is believed to signal through G protein subunits (G??s, G??i) and ??-arrestins, modulating intracellular cAMP via adenylyl cyclase and downstream effectors such as protein kinase A (PKA) and the MAPK/ERK cascade (ERK1/2). This leads to phosphorylation of CREB and transcriptional changes in pathways governing energy balance. The knockout ablates potential ligand-independent or ligand-dependent signals, allowing dissection of its role in obesity and metabolic syndrome.
In the HeLa context, GPR75 knockout creates a valuable model for examining how this receptor intersects with oncogenic and metabolic signaling. HeLa cells express a broad repertoire of GPCRs and downstream kinases, enabling cross-talk studies. The loss of GPR75 can be used to assess its contribution to cellular responses such as proliferation, glucose uptake, and lipid accumulation, which are relevant to type 2 diabetes and obesity research. This system aids in identifying downstream targets and validating GPR75 as a therapeutic target.
This knockout population is suitable for diverse applications including obesity research, GPCR signaling dissection, metabolic disease modeling, and drug target validation. Researchers can employ assays such as cAMP measurement, ERK phosphorylation detection, glucose uptake assays, and lipid accumulation quantification to phenotype the knockout. Functional screens, RT-qPCR, and Western blotting further enable characterization of signaling networks. For further details or ordering information, please contact Ascent Research.
